Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study
Женщины, мужчины и ревматоидный артрит: анализ активности заболевания, характеристик заболевания и лечения в исследовании QUEST-RA
2009-01-14
SCID: 54.1/f6u7yd6q
Discuss with AI
DAS28 remissionDisease activityGender differencesQUEST-RA StudyRheumatoid arthritis
Figures from the paper
Abstract (AI)
INTRODUCTION: Gender as a predictor of outcomes of rheumatoid arthritis (RA) has evoked considerable interest over the decades. Historically, there is no consensus whether RA is worse in females or males. Recent reports suggest that females are less likely than males to achieve remission. Therefore, we aimed to study possible associations of gender and disease activity, disease characteristics, and treatments of RA in a large multinational cross-sectional cohort of patients with RA called Quantitative Standard Monitoring of Patients with RA (QUEST-RA). METHODS: The cohort includes clinical and questionnaire data from patients who were seen in usual care, including 6,004 patients at 70 sites in 25 countries as of April 2008. Gender differences were analyzed for American College of Rheumatology Core Data Set measures of disease activity, DAS28 (disease activity score using 28 joint counts), fatigue, the presence of rheumatoid factor, nodules and erosions, and the current use of prednisone, methotrexate, and biologic agents. RESULTS: Women had poorer scores than men in all Core Data Set measures. The mean values for females and males were swollen joint count-28 (SJC28) of 4.5 versus 3.8, tender joint count-28 of 6.9 versus 5.4, erythrocyte sedimentation rate of 30 versus 26, Health Assessment Questionnaire of 1.1 versus 0.8, visual analog scales for physician global estimate of 3.0 versus 2.5, pain of 4.3 versus 3.6, patient global status of 4.2 versus 3.7, DAS28 of 4.3 versus 3.8, and fatigue of 4.6 versus 3.7 (P < 0.001). However, effect sizes were small-medium and smallest (0.13) for SJC28. Among patients who had no or minimal disease activity (0 to 1) on SJC28, women had statistically significantly higher mean values compared with men in all other disease activity measures (P < 0.001) and met DAS28 remission less often than men. Rheumatoid factor was equally prevalent among genders. Men had nodules more often than women. Women had erosions more often than men, but the statistical significance was marginal. Similar proportions of females and males were taking different therapies. CONCLUSIONS: In this large multinational cohort, RA disease activity measures appear to be worse in women than in men. However, most of the gender differences in RA disease activity may originate from the measures of disease activity rather than from RA disease activity itself.
Key Findings
1
Gender differences were statistically significant for swollen and tender joint counts, ESR, functional disability, global assessments, pain, DAS28, and fatigue, but effect sizes were small to medium.
2
In the multinational QUEST-RA cohort of 6,004 patients from 25 countries, women had worse scores across all RA disease-activity measures than men.
3
Most apparent gender differences may reflect characteristics of disease-activity measurement rather than intrinsically greater rheumatoid arthritis activity in women.
4
Rheumatoid factor prevalence was similar between genders; men had nodules more often, while women had erosions more often with only marginal statistical significance.
5
Similar proportions of women and men were receiving prednisone, methotrexate, and biologic therapies, suggesting observed activity differences were not explained by treatment utilization.
6
Women had higher mean DAS28 scores than men (4.3 versus 3.8) and achieved DAS28 remission less often, including among patients with no or minimal swollen-joint activity.
Research Object
Rheumatoid arthritis in adult women and men in the multinational QUEST-RA cohort
Research Subject
Gender differences in RA disease activity, disease characteristics, remission attainment, and use of prednisone, methotrexate, and biologic agents
Publication Details
Publication Date
2009-01-14
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest